"Lymphoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A general term for various neoplastic diseases of the lymphoid tissue.
| Descriptor ID |
D008223
|
| MeSH Number(s) |
C04.557.386 C15.604.515.569 C20.683.515.761
|
| Concept/Terms |
Lymphoma- Lymphoma
- Lymphomas
- Sarcoma, Germinoblastic
- Germinoblastic Sarcoma
- Germinoblastic Sarcomas
- Sarcomas, Germinoblastic
- Reticulolymphosarcoma
- Reticulolymphosarcomas
- Germinoblastoma
- Germinoblastomas
- Lymphoma, Malignant
- Lymphomas, Malignant
- Malignant Lymphoma
- Malignant Lymphomas
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma".
This graph shows the total number of publications written about "Lymphoma" by people in this website by year, and whether "Lymphoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2003 | 2 | 2 | 4 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 1 | 3 |
| 2015 | 1 | 0 | 1 |
| 2017 | 38 | 10 | 48 |
| 2018 | 31 | 11 | 42 |
| 2019 | 10 | 5 | 15 |
| 2020 | 4 | 3 | 7 |
| 2021 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphoma" by people in Profiles.
-
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies. Haematologica. 2022 03 01; 107(3):715-720.
-
Serologic response to mRNA COVID-19 vaccination in lymphoma patients. Am J Hematol. 2021 11 01; 96(11):E410-E413.
-
Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients. Br J Haematol. 2021 11; 195(4):523-531.
-
BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am J Hematol. 2021 10 01; 96(10):1195-1203.
-
Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. Lancet Haematol. 2021 Aug; 8(8):e542-e544.
-
Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient. Cancer Cell. 2021 08 09; 39(8):1037-1038.
-
COVID-19 vaccination in patients on rituximab: a survey of lymphoma physicians at NCI designated cancer centers. Leuk Lymphoma. 2021 12; 62(12):3019-3022.
-
COVID-19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience. Br J Haematol. 2021 08; 194(4):e74-e77.
-
Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review. Am J Clin Dermatol. 2021 Jul; 22(4):425-442.
-
COVID-19 mRNA Vaccination-Induced Lymphadenopathy Mimics Lymphoma Progression on FDG PET/CT. Clin Nucl Med. 2021 04 01; 46(4):353-354.